



**Pharmacy Updates
September-November 2018**

CenCal Health has made several changes to our Formulary based on clinical review, provider interest, cost and utilization analysis. All of the changes represent development and growth of our current Formulary thus giving more choices to the prescribing physician. The changes are represented in summary on the chart below.

Drug	Class	Formulary Status	Restrictions / Limits	Implementation Date
Formulary Additions				
Nivestym 300mcg/0.5ml 480mcg/0.8ml	Hematopoietic Agents	Formulary: Quantity Restriction	Restriction: Quantity limit of three (3) 300mcg vials/syringes or two (2) 480mcg/vials/syringes per fill Day supply limit maximum 10-day supply in 30 days.	11/1/2018
Yuvafem 10mcg	Estrogens	Formulary: Quantity Restriction	Restriction: Quantity limit of 8 tablets per 28 days.	11/1/2018
Formulary Changes				
Aimovig 70mg/ml Auto In	Antimigraine Preparations	Non-Formulary	Mandatory Fulfillment through Diplomat Specialty	9/1/2018
Ajovy 225mg/1.5ml Syringe	Antimigraine Preparations	Non-Formulary	Mandatory Fulfillment through Diplomat Specialty	10/1/2018
Rizatriptan ODT	Antimigraine Preparations	Formulary	Removed Step Therapy	10/1/2018
Triptan Step Therapy: Sumatriptan, Rizatriptan 1st line agents	Antimigraine Preparations	Formulary	Restriction: Step Therapy 2nd line agents Naratriptan, Eletriptan, Zolmitriptan, Frovatriptan DS should be 20 with a history period of 120 days. Concurrent use edit will remain	10/1/2018
Ilumya 100mg/ml Syringe	Antipsoriatic Agents	Non-Formulary	Mandatory Fulfillment through Diplomat Specialty	10/1/2018